Feline Aortic Thromboembolism

Feline Aortic Thromboembolism (FATE) is a life-threatening cardiovascular emergency in cats characterized by the formation and lodging of a blood clot — typically at the aortic trifurcation (the "saddle thrombus") — causing acute interruption of blood flow to the hindlimbs and, less commonly, to a forelimb or other vascular territories [1]. The syndrome is encountered frequently in emergency and critical care settings and is almost always a secondary consequence of severe underlying cardiac disease, most notably hypertrophic cardiomyopathy [1][7]. The sudden onset, extreme pain, and rapid clinical deterioration make FATE one of the most dramatic and distressing presentations in feline medicine [1]. Despite advances in supportive care and emerging thrombolytic therapies, the short- and long-term prognosis remains guarded to poor, with high early mortality rates [1][2].

Underlying Cardiac Disease The overwhelming majority of FATE cases arise secondary to structural heart disease. Hypertrophic cardiomyopathy (HCM) is by far the most common predisposing condition, followed by other cardiomyopathies (dilated, restrictive, unclassified) [1][7]. These diseases lead to left atrial enlargement and impaired intracardiac blood flow, creating the substrate for thrombus formation within the left atrium or left atrial appendage [1].

Virchow's Triad in FATE The pathophysiology of thrombogenesis in FATE follows the classic Virchow's triad:

1. ·Blood stasis: Left atrial dilation and reduced cardiac output result in sluggish, turbulent blood flow within the left atrium, promoting clot formation [1][7].
2. ·Endothelial injury: Chronically elevated intracardiac pressures and altered wall stress contribute to endothelial dysfunction and activation of the coagulation cascade [1].
3. ·Hypercoagulability: Platelet activation and upregulation of procoagulant factors have been documented in cats with cardiomyopathy, further promoting thrombogenesis [1].

Thrombus Formation and Embolization A thrombus — most often originating from the left atrium — dislodges and travels through the arterial circulation. The aortic trifurcation (the junction of the aorta into the two common iliac arteries) is the most frequent site of lodgment, producing a "saddle thrombus" [1][7]. Less commonly, thromboemboli lodge in the brachial, renal, mesenteric, or cerebral arteries [1].

Ischemic Consequences Once lodged, the thrombus causes mechanical obstruction and vasoactive mediator release (e.g., serotonin, thromboxane A₂), inducing intense collateral vasospasm that worsens ischemia beyond what the mechanical obstruction alone would cause [1]. This results in ischemic neuropathy and myopathy of the affected limb(s), explaining the flaccid paralysis, cold extremities, and intense pain [1]. Prolonged ischemia leads to muscle necrosis, rhabdomyolysis, and — upon reperfusion — systemic release of potassium and myoglobin, which can cause life-threatening hyperkalemia and acute kidney injury [1][2].

Clinical Diagnosis The diagnosis is often made on clinical grounds alone based on the highly characteristic presentation: acute pelvic limb paralysis, absence of femoral pulses, cold and cyanotic distal extremities, and pain in a cat with known or suspected cardiac disease [1][7]. Clinical confirmation criteria include at least one of several objective findings (see below) [2].

Confirmatory Diagnostic Criteria (used in clinical trials) In the BLASTT study, confirmation of FATE required clinical signs plus at least one of the following: Doppler ultrasound confirming absent flow in the femoral arteries, point-of-care ultrasound (POCUS) demonstrating a cardiac or aortic thrombus, or infrared thermographic evidence of a significant temperature gradient between affected and unaffected limbs [2].

Doppler Ultrasound Handheld Doppler probes placed over the femoral arteries can rapidly confirm absent or severely reduced arterial flow, supporting the diagnosis at the bedside without requiring full echocardiography [1].

Infrared Thermography A prospective study demonstrated that infrared thermography is a rapid and highly accurate tool for distinguishing FATE from non-ischemic causes of acute pelvic paralysis [3]. Cats with FATE exhibit a marked temperature differential between affected hindlimb extremities and unaffected body regions. Sensitivity and specificity were high, making it a valuable point-of-care diagnostic adjunct in emergency settings [3].

Echocardiography Full echocardiographic examination is essential to characterize the underlying cardiac disease, assess left atrial size (left atrial to aortic root ratio, LA:Ao), identify the source thrombus within the left atrium or left atrial appendage, and guide long-term management [1][7]. Spontaneous echocardiographic contrast ("smoke") in the left atrium is a marker of blood stasis and thromboembolic risk [1].

Point-of-Care Ultrasound (POCUS) POCUS enables rapid assessment of cardiac structure and function, detection of pleural or pericardial effusion, and sometimes direct visualization of an aortic thrombus, all without the need for sedation or specialized equipment [1][2].

Laboratory Findings Laboratory abnormalities in FATE reflect ischemic tissue injury, rhabdomyolysis, and cardiac compromise:

• ·Elevated creatine kinase (CK): Markedly elevated due to ischemic muscle damage and rhabdomyolysis [1][7]
• ·Hyperkalemia: Released from necrotic muscle cells; can cause life-threatening cardiac arrhythmias [1][2]
• ·Elevated BUN and CREA (azotemia): Prerenal azotemia from low cardiac output and/or renal thromboembolism [1][7]
• ·Elevated ALT: May be elevated due to hepatic ischemia in severe cases [7]
• ·Elevated lactate: Reflects peripheral tissue hypoperfusion and anaerobic metabolism [1]
• ·Low HCT (anemia) or hemoconcentration: Variable depending on hydration status and chronicity [7]
• ·Thrombocytopenia (low PLT): Consumption of platelets during thrombus formation [1]
• ·Elevated TBIL: May occur with hepatic congestion in concurrent CHF [7]
• ·Hypoalbuminemia (low ALB): May reflect chronic disease, poor nutritional status, or protein-losing processes in cats with long-standing cardiac disease [7]
• ·Elevated glucose: Stress hyperglycemia is common in acute FATE presentations [1]
• ·Blood gas abnormalities: Metabolic acidosis due to lactic acidosis and tissue ischemia [1]

Electrocardiography (ECG) ECG may reveal arrhythmias (e.g., ventricular premature contractions) associated with the underlying cardiomyopathy or secondary to hyperkalemia-induced changes [7].

Thoracic Radiography Chest radiographs are useful to assess for concurrent pulmonary edema or pleural effusion from CHF, which directly impacts treatment decisions and prognosis [1][7].

Management of FATE requires simultaneous stabilization of the cardiovascular emergency, analgesia, treatment of the thromboembolism, and management of the underlying cardiac disease [1][2].

Analgesia (First Priority) Pain management is a critical and immediate priority. Opioids (e.g., methadone, buprenorphine, fentanyl by constant rate infusion) are the analgesics of choice and should be administered without delay [1][2]. The BLASTT trial mandated that all enrolled cats receive standardized analgesia regardless of treatment group [2].

Cardiovascular Stabilization

• ·Concurrent CHF (pulmonary edema, pleural effusion) is treated with furosemide (diuresis) and, if needed, oxygen supplementation [1][7].
• ·Hypothermia should be addressed with gentle warming (avoiding excessive heat to ischemic limbs).
• ·Severe hypotension warrants cautious cardiovascular support [1].
• ·Hyperkalemia-induced arrhythmias may require calcium gluconate, sodium bicarbonate, or dextrose/insulin therapy [1].

Anticoagulation Therapy (Standard of Care) Anticoagulation aims to prevent propagation of the existing thrombus and reduce the risk of new thromboembolic events:

• ·Unfractionated heparin (UFH): Traditionally used in the acute setting at a loading dose followed by constant rate infusion or intermittent subcutaneous dosing; monitored by anti-Xa activity or activated partial thromboplastin time (aPTT) [1][7].
• ·Low molecular weight heparin (LMWH, e.g., dalteparin, enoxaparin): Increasingly used due to more predictable pharmacokinetics and subcutaneous administration [1].
• ·Warfarin: Has historically been used for long-term anticoagulation but requires careful monitoring of prothrombin time/INR [7].
• ·Clopidogrel: An antiplatelet agent that is widely used for long-term secondary prevention of recurrent FATE; shown to reduce recurrence risk in cats [1].
• ·Rivaroxaban: A novel oral anticoagulant (NOAC) being studied and used in cats as an alternative for long-term prevention [1].

Thrombolytic Therapy — Tissue Plasminogen Activator (tPA) Thrombolysis directly targets clot dissolution and represents the most direct treatment approach:

• ·The BLASTT trial — the first prospective, multicenter, double-blinded, randomized, placebo-controlled study of tPA in FATE — enrolled cats with ≥2 limbs affected within 6 hours of onset [2]. Cats received tPA at 1 mg/kg/h with the first 10% administered as a bolus, or placebo, alongside standardized analgesia and supportive care [2]. Preliminary results provided important data on feasibility, safety, and efficacy signals [2].
• ·A retrospective study of 16 FATE cats treated with tPA found that tPA-treated cats showed evidence of limb reperfusion; however, hemorrhagic complications were observed and outcomes did not clearly demonstrate superiority over standard of care, highlighting the risk-benefit complexity [4].
• ·A broader clinical review of tPA use in dogs and cats documented its use across various thrombotic conditions, reinforcing the need for careful patient selection due to bleeding risks [5].
• ·Local intra-arterial urokinase has been reported as an alternative in a single case report, where a cat that did not respond to IV urokinase or heparin achieved successful thrombolysis via catheter-directed intra-arterial urokinase on day 3 [6].

Monitoring During Thrombolytic Therapy Cats receiving tPA require close monitoring for reperfusion syndrome (sudden release of potassium and myoglobin from ischemic tissue), hemorrhagic complications, arrhythmias, and azotemia [2][4].

Supportive Care

• ·Nutritional support and fluid therapy (carefully balanced against cardiac function) [7]
• ·Physical rehabilitation of affected limbs during recovery [1]
• ·Treatment of rhabdomyolysis and myoglobinuria with IV fluids to protect renal function [1]
• ·Nursing care for recumbent cats (padding, turning, bladder expression) [7]

Euthanasia Consideration Given the severity of the syndrome, intense pain, poor prognosis, and welfare concerns, humane euthanasia is a legitimate and compassionate option that should be openly discussed with owners at presentation [1][7].

FATE carries a grave short-term prognosis, and survival statistics must be communicated clearly to cat owners at the time of diagnosis [1][2].

Short-Term Mortality

• ·FATE is associated with extremely high early mortality. A substantial proportion of cats either die or are euthanized within the first 24–72 hours of presentation [1][7].
• ·In the Hassan et al. study of 15 cats managed with multimodal anticoagulant therapy, outcomes were poor overall, with significant mortality reflecting the severity of the syndrome [7].
• ·In the retrospective tPA study of 16 cats, short-term survival rates did not clearly differ between tPA-treated cats and standard-of-care controls, and hemorrhagic complications were a concern in the tPA group [4].
• ·The BLASTT prospective randomized controlled trial was specifically designed to assess whether tPA improves survival and reperfusion outcomes in the acute setting, underscoring that survival benefit from thrombolysis remained an open question requiring formal investigation [2].

Concurrent CHF as a Prognostic Factor The presence of concurrent congestive heart failure at the time of FATE significantly worsens the prognosis, as respiratory compromise adds to hemodynamic instability and limits treatment options [1][7].

Prognostic Indicators Poor prognostic signs include: bilateral limb involvement, hypothermia, severe respiratory distress, severe azotemia, hyperkalemia, and evidence of multi-organ ischemia [1][7].

Recurrence Risk Cats that survive an initial FATE episode remain at high risk for recurrence due to the persistence of the underlying cardiac disease and the prothrombotic state [1]. Long-term antiplatelet or anticoagulant therapy (clopidogrel, rivaroxaban) is essential to reduce — but cannot eliminate — recurrence risk [1].

Long-Term Survival Long-term prognosis is heavily determined by the severity of the underlying cardiac disease. Cats with well-controlled cardiomyopathy and no recurrent FATE events may achieve a reasonable quality of life for months to years, but overall median survival times post-FATE are reported to be relatively short in the veterinary literature [1].

Management of Underlying Cardiac Disease The most effective strategy for preventing FATE is early detection and management of predisposing cardiac conditions, particularly hypertrophic cardiomyopathy [1][7]. Regular cardiac screening — including auscultation, blood pressure measurement, biomarker testing (NT-proBNP, cardiac troponin I), and echocardiography — is recommended for at-risk breeds (e.g., Maine Coon, Ragdoll, British Shorthair) and any cat with a detected heart murmur [1].

Long-Term Antiplatelet and Anticoagulant Therapy In cats diagnosed with significant cardiomyopathy — especially those with left atrial enlargement or a history of FATE — long-term antithrombotic therapy is the primary preventive intervention [1]:

• ·Clopidogrel (antiplatelet): The FATCAT study demonstrated that clopidogrel was superior to aspirin in preventing recurrent FATE in cats, and it is currently considered the first-line agent for secondary prevention [1].
• ·Rivaroxaban: An emerging oral anticoagulant being investigated and used in clinical practice for cats at high thromboembolic risk, particularly those with severely enlarged left atria [1].
• ·Aspirin: Historically used but now largely supplanted by clopidogrel given evidence of inferior efficacy [1].

Monitoring and Follow-Up Regular echocardiographic reassessment allows clinicians to track disease progression, adjust antithrombotic therapy, and manage evolving CHF — all of which indirectly reduce FATE risk [1].

Breeder Screening Programs For breeds with heritable HCM (notably Maine Coon and Ragdoll cats, where specific sarcomeric gene mutations are known), genetic testing and echocardiographic screening programs in breeding populations aim to reduce the prevalence of cardiomyopathy and thereby reduce downstream FATE risk [1].